CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 1, 2011

Primary Completion Date

November 7, 2016

Study Completion Date

November 7, 2017

Conditions
Hypogonadism
Interventions
DRUG

Testosterone Cypionate

"Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61."

Trial Locations (2)

77030

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

87108-5153

New Mexico VA Health Care System, Albuquerque, NM, Albuquerque

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

lead

VA Office of Research and Development

FED

NCT01378299 - CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy | Biotech Hunter | Biotech Hunter